> The FDA has granted a priority review of Merck's cancer drug Zolinza. The therapy is designed to treat advanced cutaneous T-cell lympyhoma, a cancer of white blood cells. Merck says it expects a decision on Zolinza by October. Report
> Origen Therapeutics says it has designed new techniques for producing genetically altered chickens which can produce drugs. The field of transgenics has attracted growing interest since GTC Biotherapeutics' recent ability to gain the EMEA approve of a new therapy from goat's milk. Report
> Chutes & Ladders: Digene Chairman and CEO Evan Jones has announced plans to retire. Report
> MediGene announced that it had won a patent fight in Europe over cancer-killing HSV. Report
> Haemonetics has acquired the outstanding shares of Arryx it doesn't already own for $26 million. The two companies have been collaborating on a new method for blood separation and processing. Release
> GlobeImmune has launched a Phase II clinical trial of GI-4000, a therapeutic vaccine for the treatment of patients with early-stage pancreas cancer. Release
> GPC Biotech says it will continue with a late-stage trial of Satraplatin following clearance from an independent monitoring board. Report
> Denmark's Genmab announced today that HuMax-CD38 was shown to inhibit the enzymatic activity of the CD38 molecule in preclinical studies. Release
> Merck KGaA confirmed that it holds more than five percent of Schering shares. Release
> Laureate Pharma has announced plans to invest $9 million in its Princeton, NJ plant. Release
> Repligen has begun a trial for a new imaging agent. Report
> In a new study, researchers say the market for protein therapeutics has more than doubled in four years. Report
> Canada's Cannasat Therapeutics has gained $5 million in financing. Release
And Finally... Connecticut's stem cell program has attracted proposals from 77 scientists. Article